Peter W Heymann1, Thomas A E Platts-Mills2, Judith A Woodfolk2, Larry Borish2, Deborah D Murphy3, Holliday T Carper3, Mark R Conaway4, John W Steinke2, Lyndsey Muehling2, W Gerald Teague5, Joshua L Kennedy6, Anne-Marie Irani7, Matthew D McGraw8, Stephen V Early9, Lisa M Wheatley10, Amy P Adams11, Ronald B Turner12. 1. Asthma and Allergic Diseases Center, University of Virginia, Charlottsville, Va; Division of Pediatric Respiratory Medicine, University of Virginia, Charlottsville, Va. Electronic address: pwh5a@virginia.edu. 2. Asthma and Allergic Diseases Center, University of Virginia, Charlottsville, Va. 3. Asthma and Allergic Diseases Center, University of Virginia, Charlottsville, Va; Division of Pediatric Respiratory Medicine, University of Virginia, Charlottsville, Va. 4. Department of Public Health Sciences, University of Virginia, Charlottsville, Va. 5. Division of Pediatric Respiratory Medicine, University of Virginia, Charlottsville, Va. 6. Division of Allergy and Immunology, University of Arkansas for Medical Sciences, Little Rock, Ark. 7. Division of Pediatric Allergy and Immunology, Virginia Commonwealth University, Richmond, Va. 8. Division of Pediatric Pulmonology, University of Rochester, Rochester, NY. 9. Division of Pediatric Otolaryngology, University of Virginia, Charlottsville, Va. 10. Allergy, Asthma and Airways Biology Branch, Division of Allergy, Immunology, and Transplantation/National Institute of Allergy and Infectious Diseases, Bethesda, Md. 11. Department of Pharmacy, University of Virginia, Charlottsville, Va. 12. Department of Pediatric Infectious Diseases, University of Virginia, Charlottsville, Va.
Abstract
BACKGROUND: Rhinovirus frequently causes asthma exacerbations among children and young adults who are allergic. The interaction between allergen and rhinovirus-induced symptoms and inflammation over time is unclear. OBJECTIVE: Our aim was to compare the response to an experimental inoculation with rhinovirus-16 in allergic asthmatics with the response in healthy controls and to evaluate the effects of administrating omalizumab before and during the infection. METHODS: Two clinical trials were run in parallel. In one of these trials, the response to an experimental inoculation with rhinovirus-16 among asthmatics with high levels of total IgE was compared to the response in healthy controls. The other trial compared the effects of administering omalizumab versus placebo to asthmatics in a randomized, double-blind placebo-controlled investigation. The primary outcome for both trials compared lower respiratory tract symptoms (LRTSs) between study groups over the first 4 days of infection. RESULTS: Frequent comparisons of symptoms, lung function, and blood eosinophil counts revealed differences that were more pronounced among allergic asthmatics than among controls by days 2 and 3 after virus inoculation. Additionally, an augmentation of upper respiratory tract symptom scores and LRTS scores occurred among the atopic asthmatics versus the controls during the resolution of symptoms (P < .01 for upper respiratory symptom tract scores and P < .001 for LRTS scores). The beneficial effects of administering omalizumab on reducing LRTSs and improving lung function were strongest over the first 4 days. CONCLUSIONS:LRTSs and blood eosinophil counts were augmented and lung function was reduced among allergic asthmatics early after rhinovirus inoculation but increased late in the infection during symptom resolution. The effect of administering omalizumab on the response to rhinovirus was most pronounced during the early/innate phase of the infection.
RCT Entities:
BACKGROUND:Rhinovirus frequently causes asthma exacerbations among children and young adults who are allergic. The interaction between allergen and rhinovirus-induced symptoms and inflammation over time is unclear. OBJECTIVE: Our aim was to compare the response to an experimental inoculation with rhinovirus-16 in allergic asthmatics with the response in healthy controls and to evaluate the effects of administrating omalizumab before and during the infection. METHODS: Two clinical trials were run in parallel. In one of these trials, the response to an experimental inoculation with rhinovirus-16 among asthmatics with high levels of total IgE was compared to the response in healthy controls. The other trial compared the effects of administering omalizumab versus placebo to asthmatics in a randomized, double-blind placebo-controlled investigation. The primary outcome for both trials compared lower respiratory tract symptoms (LRTSs) between study groups over the first 4 days of infection. RESULTS: Frequent comparisons of symptoms, lung function, and blood eosinophil counts revealed differences that were more pronounced among allergic asthmatics than among controls by days 2 and 3 after virus inoculation. Additionally, an augmentation of upper respiratory tract symptom scores and LRTS scores occurred among the atopic asthmatics versus the controls during the resolution of symptoms (P < .01 for upper respiratory symptom tract scores and P < .001 for LRTS scores). The beneficial effects of administering omalizumab on reducing LRTSs and improving lung function were strongest over the first 4 days. CONCLUSIONS: LRTSs and blood eosinophil counts were augmented and lung function was reduced among allergic asthmatics early after rhinovirus inoculation but increased late in the infection during symptom resolution. The effect of administering omalizumab on the response to rhinovirus was most pronounced during the early/innate phase of the infection.
Authors: Robert F Lemanske; Daniel J Jackson; Ronald E Gangnon; Michael D Evans; Zhanhai Li; Peter A Shult; Carol J Kirk; Erik Reisdorf; Kathy A Roberg; Elizabeth L Anderson; Kirstin T Carlson-Dakes; Kiva J Adler; Stephanie Gilbertson-White; Tressa E Pappas; Douglas F Dasilva; Christopher J Tisler; James E Gern Journal: J Allergy Clin Immunol Date: 2005-09 Impact factor: 10.793
Authors: G P Rakes; E Arruda; J M Ingram; G E Hoover; J C Zambrano; F G Hayden; T A Platts-Mills; P W Heymann Journal: Am J Respir Crit Care Med Date: 1999-03 Impact factor: 21.405
Authors: William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245
Authors: Ann Esquivel; William W Busse; Agustin Calatroni; Alkis G Togias; Kristine G Grindle; Yury A Bochkov; Rebecca S Gruchalla; Meyer Kattan; Carolyn M Kercsmar; G Khurana Hershey; Haejin Kim; Petra Lebeau; Andrew H Liu; Stanley J Szefler; Stephen J Teach; Joseph B West; Jeremy Wildfire; Jaqueline A Pongracic; James E Gern Journal: Am J Respir Crit Care Med Date: 2017-10-15 Impact factor: 21.405
Authors: Sandy R Durrani; Daniel J Montville; Allison S Pratt; Sanjukta Sahu; Mark K DeVries; Victoria Rajamanickam; Ronald E Gangnon; Michelle A Gill; James E Gern; Robert F Lemanske; Daniel J Jackson Journal: J Allergy Clin Immunol Date: 2012-07-04 Impact factor: 10.793
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: David J Jackson; Heidi Makrinioti; Batika M J Rana; Betty W H Shamji; Maria-Belen Trujillo-Torralbo; Joseph Footitt; Aurica G Telcian; Alexandra Nikonova; Jie Zhu; Julia Aniscenko; Leila Gogsadze; Eteri Bakhsoliani; Stephanie Traub; Jaideep Dhariwal; James Porter; Duncan Hunt; Toby Hunt; Trevor Hunt; Luminita A Stanciu; Musa Khaitov; Nathan W Bartlett; Michael R Edwards; Onn Min Kon; Patrick Mallia; Nikolaos G Papadopoulos; Cezmi A Akdis; John Westwick; Matthew J Edwards; David J Cousins; Ross P Walton; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2014-12-15 Impact factor: 21.405
Authors: Trevor T Hansel; Tanushree Tunstall; Maria-Belen Trujillo-Torralbo; Betty Shamji; Ajerico Del-Rosario; Jaideep Dhariwal; Paul D W Kirk; Michael P H Stumpf; Jens Koopmann; Aurica Telcian; Julia Aniscenko; Leila Gogsadze; Eteri Bakhsoliani; Luminita Stanciu; Nathan Bartlett; Michael Edwards; Ross Walton; Patrick Mallia; Toby M Hunt; Trevor L Hunt; Duncan G Hunt; John Westwick; Matthew Edwards; Onn Min Kon; David J Jackson; Sebastian L Johnston Journal: EBioMedicine Date: 2017-03-28 Impact factor: 8.143
Authors: Lyndsey M Muehling; Peter W Heymann; Paul W Wright; Jacob D Eccles; Rachana Agrawal; Holliday T Carper; Deborah D Murphy; Lisa J Workman; Carolyn R Word; Sarah J Ratcliffe; Brian J Capaldo; Thomas A E Platts-Mills; Ronald B Turner; William W Kwok; Judith A Woodfolk Journal: J Allergy Clin Immunol Date: 2020-04-19 Impact factor: 10.793
Authors: Jaideep Dhariwal; Aoife Cameron; Ernie Wong; Malte Paulsen; Maria-Belen Trujillo-Torralbo; Ajerico Del Rosario; Eteri Bakhsoliani; Tatiana Kebadze; Mark Almond; Hugo Farne; Leila Gogsadze; Julia Aniscenko; Batika M J Rana; Trevor T Hansel; David J Jackson; Onn Min Kon; Michael R Edwards; Roberto Solari; David J Cousins; Ross P Walton; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2021-12-01 Impact factor: 30.528
Authors: Lyndsey M Muehling; Peter W Heymann; Holliday Carper; Deborah D Murphy; Evan Rajadhyaksha; Joshua Kennedy; Stephen V Early; Manuel Soto-Quiros; Lydiana Avila; Lisa Workman; Thomas A E Platts-Mills; Judith A Woodfolk Journal: Clin Exp Allergy Date: 2022-06-06 Impact factor: 5.401
Authors: Mário Morais-Almeida; Rita Aguiar; Bryan Martin; Ignacio J Ansotegui; Motohiro Ebisawa; L Karla Arruda; Marco Caminati; Giorgio Walter Canonica; Tara Carr; Geoffrey Chupp; Jonathan Corren; Ignacio Dávila; Hae-Sim Park; Nicola A Hanania; Lanny Rosenwasser; Mario Sánchez-Borges; J Christian Virchow; Anahí Yáñez; Jonathan A Bernstein; Luis Caraballo; Yoon-Seok Chang; Manana Chikhladze; Alessandro Fiocchi; Sandra N González-Diaz; Luciana Kase Tanno; Michael Levin; Jose António Ortega-Martell; Giovanni Passalacqua; David B Peden; Philip W Rouadi; James L Sublett; Gary W K Wong; Eugene R Bleecker Journal: World Allergy Organ J Date: 2020-05-16 Impact factor: 4.084
Authors: Britney A Helling; Débora R Sobreira; Grace T Hansen; Noboru J Sakabe; Kaixuan Luo; Christine Billstrand; Bharathi Laxman; Raluca I Nicolae; Dan L Nicolae; Yury A Bochkov; James E Gern; Marcelo A Nobrega; Steven R White; Carole Ober Journal: Commun Biol Date: 2020-11-13